| Primary information |
|---|
| sequence ID | Seq_7750 |
| Peptide sequence | SSYSKQFTSSTSYNRGDST |
| CancerPDF_ID | CancerPDF_ID1274, CancerPDF_ID9693, CancerPDF_ID11054, CancerPDF_ID12301, |
| PMID | 21136997,21533267,26993605,26992070 |
| Protein Name | Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,"FIBA_HUMAN,",FIBA_HUMAN |
| Fluid | Serum,Serum,Serum,Serum |
| M/Z | 2101.91886,701.65,2102.7,NA |
| Charge | 1,3,NA,NA |
| Mass (in Da) | NA,NA,NA,2102.930393 |
| fdr | NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,MALDI-TOF,LC-MS |
| Peptide Identification technique | LC-MS-MS/MS,LC/MS/MS,LTQ-Orbitrap-MS/MS,LC-MS/MS |
| Quantification Technique | LC-ESI-MS,Multiple Reaction Monitoring,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free |
| FDR | 0.001,1.49,less than 0.000004,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID1274, CancerPDF_ID9693, CancerPDF_ID11054, CancerPDF_ID12301, |
| p-Value | 3.71E-04,NA,less than 0.05,NA |
| Software | MASCOT(v. 2.2.01),MASCOT,SEQUEST,SEQUEST and Maxquant |
| Length | 19,19,19,19 |
| Cancer Type | Colorectal cancer,Lung adenocarcinoma,Esophageal squamous cell carcinoma (ESCC),Melanoma |
| Database | SwissProt Database,Swissprot Database (57.4),IPI Human Database (3.45),SwissProt Database |
| Modification | NA,NA,NA,NA |
| Number of Patients | 30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,for training 100 ESCC patients and 98 healthy individuals were used and for validation 101 ESCC patients and 98 healthy individuals were used,8 cancer samples and 4 healthy samples |
| Regulation | Differentially expressed between cancer vs normal,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Upregulated in ESCC patients vs control with mean intensity in cancer as 532.28 and mean intensity in control as 266.24,"Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." |
| Validation | Leave One out Cross validation,MRM-based validation of 19 candidates,external cross validation done,na |
| Sensitivity | 0.898,NA,97% on training dataset and 97.3 on validation dataset,NA |
| Specificity | 0.946,NA,95.92% on training dataset and 100% on validation dataset,NA |
| Accuracy | 0.917,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |